With a market cap of $120.8 billion, CVS Health Corporation (CVS) delivers a wide range of services through its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. It provides insurance products, pharmacy benefit management, and retail pharmacy services to individuals, employers, and government programs.
The Woonsocket, Rhode Island-based company is slated to announce its fiscal Q3 2026 results before the market opens on Wednesday, Nov. 4. Ahead of the event, analysts expect CVS to report an adjusted EPS of $1.62, up 1.3% from $1.60 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in each of the past four quarterly reports.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts predict CVS Health to post adjusted EPS of $8.02, a 18.8% increase from $6.75 in fiscal 2025.
www.barchart.com Shares of CVS Health have risen 15.9% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 13.6% gain. However, the stock has lagged behind the State Street Health Care Select Sector SPDR ETF's (XLV) 22.9% return over the same period.
www.barchart.com Despite reporting better-than-expected Q2 2026 adjusted EPS of $2.58, CVS Health shares tumbled 5.1% on Aug. 5. The company raised its 2026 EPS forecast by $0.60 at both ends to $7.90 - $8.10, but projected only single-digit earnings growth in the second half, while its initial 2027 outlook of at least $8.44 per share offered little upside beyond existing expectations. Additional concerns included weaker expected client retention and regulatory pressure on its Caremark pharmacy benefit management business, alongside uncertainty over rising medical costs and macroeconomic conditions.
Analysts' consensus rating on CVS stock is bullish, with an overall "Strong Buy" rating. Among 24 analysts covering the stock, 20 recommend a "Strong Buy,” two have a "Moderate Buy" rating, and two give a "Hold" rating. The average analyst price target is $113.46, indicating a potential upside of 21% from the current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Meta Stock Is Under Pressure as AI Costs and Legal Bills Mount. Here Are 4 Things Investors Need to Watch. Dear Amazon Stock Fans, Mark Your Calendar for October 29 This Stock Is Hot at New 52-Week Highs. But It Now for Profit Growth Ahead. The Biggest Merger Ever: Tesla and SpaceX Could Combine and Give Elon Musk 56% Control